Seminar Business life
                        |
                        Friday April 4, 1997
                        
                                            
                    
                    
                                                    The discovery of RU 486, which terminates pregnancy, was an exceptional scientific and medical event, but became the subject of an enormous ethical debate, and even prompted the revival of the argument about abortion. The correct method for marketing this drug has still not been found, but Édouard Sakiz, who has always assumed entire responsability for this project, continues, against all odds, to work towards the development of this compound.
                                            
                    
                    
                                                                
                                            
                                                            
                                    The entire article was written by:
                                                                            Lucien CLAES
                                                                     
                            
                                                     
                        
                                                                                                            
                                
                                    
                                        
                                        
                                            
                                                This session was published in issue n°6 of the Journal de l'École de Paris du management, entitled
                                                L'esprit de conquête .
                                            
                                         
                                     
                                 
                                                    
                                                
                                                
                                                	
                                                	
                                                
                                                 
        
No comments yet